V-LAP · A revolutionary direct, daily heart monitoring platform for long-term tailored treatment of Heart Disease patients.

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enoughblood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swellingand tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate HeartFailure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% oftotal healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF,whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliestindicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV duringpatient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimallyinvasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: viainductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit whichsynchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/redcolor code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manageglucose levels in diabetes.